Purpose-built AI tools and implementation services for biotech, pharma, and AEC organizations, where the stakes are too high for generic solutions.
Most organizations in biotech, pharma, and AEC are at an early stage of AI adoption, aware of the potential, uncertain about where to start, and rightly cautious about regulated environments. Catalyst Group bridges that gap.
We understand both the technology and the industry context, allowing us to identify the highest-value AI applications, design compliant implementation pathways, and deliver working solutions, not proof-of-concept slides.
Our AI practice covers everything from strategic AI readiness assessments through full product development and deployment. We also develop proprietary AI products tailored to specific challenges in project management, quality assurance, and operational performance in life sciences settings.
Evaluating your data infrastructure, organizational maturity, and highest-value AI use cases.
A prioritized implementation plan aligned to your business objectives and regulatory constraints.
Deploying AI and intelligent automation to reduce manual work, improve data quality, and accelerate decisions.
Building models that anticipate equipment failures, supply chain disruptions, batch deviations, and schedule risks.
Embedding AI capabilities into CapEx and OpEx programs to improve cost control, scheduling, and risk management.
Purpose-built tools for life sciences and AEC, available as licensed products or co-developed with clients.
Ensuring AI implementations meet GxP, regulatory, and data privacy requirements.
Catalyst Group drives the commercial and operational leadership of MEPAIA — an AI platform built from the ground up for MEP engineering in life sciences, pharma, and AEC.
MEPAIA is an AI-powered automation platform embedded directly in Autodesk Revit. It eliminates the most time-consuming MEP engineering tasks — voice-driven command execution, intelligent pipe and duct routing, pressure drop calculations, insulation specification, HVAC zoning, and automated GMP documentation — allowing engineers to move from repetitive manual modelling to higher-value design decisions.
The platform pairs deterministic engineering logic (every calculation auditable and traceable to Revit element IDs) with generative AI for natural language interpretation and adaptive routing — making it uniquely suited to FDA and EMA regulated environments where accuracy is non-negotiable.
Designed for engineering firms delivering pharmaceutical and biotech facilities, MEPAIA addresses the specific demands of GMP-compliant design: room pressurization drawings, air volume calculations, reflected ceiling plan generation, and MTO creation. It compresses delivery timelines on the most document-heavy phases of facility design without compromising accuracy or regulatory compliance.
Catalyst Group provides the commercial and operational leadership behind MEPAIA — from go-to-market strategy and industry positioning to partner development and operational governance. We bring our depth in both life sciences and AEC to ensure the platform is deployed where it creates the most value: inside the engineering firms designing the world's most complex regulated facilities.
This is what Catalyst Group's AI practice looks like in practice: not consulting on AI in the abstract, but leading the commercialization of a real, working product in a market we know deeply.
Visit the MEPAIA website to explore platform capabilities, the product roadmap, and how your engineering team can gain early access.
Visit MEPAIA.ai →The life sciences organizations that invest in AI now will have structural advantages in cost, speed, and quality within 3–5 years that will be very difficult for laggards to close. The window to build a competitive AI capability, rather than catch up to one, is open now. Catalyst Group helps you use it.
Evaluating how AI can reduce cost, improve quality, or accelerate timelines.
Looking to differentiate their offering through technology-enabled services.
Working on life sciences facilities who want AI-driven project delivery capabilities.
That have tried generic AI tools and found them unfit for regulated environments.
Start with a free 30-minute AI Opportunity conversation. We'll help you identify the highest-value use cases and tell you honestly what's feasible.